Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

Int J Mol Sci · 2025 · PMC12296095 · PMID 40725183

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For patients with SCC, there was a trend toward OS benefit for the pembrolizumab group ( p = 0.088); however, pembrolizumab showed a trend toward better OS for those without TP53 mutation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.